When given in combination with Kyprolis (carfilzomib), the investigative therapy Reolysin (pelareorep) elicits a strong inflammatory response — and promising clinical responses…
Researchers are continuing to study how the combination of Oncolytics Biotech‘s virus-based anti-cancer therapy Reolysin (pelareorep) and Kyprolis (carfilzomib) provides benefits…
A Phase 1 trial of the combination of Reolysin (pelareorep), Kyprolis (carfilzomib), and Opdivo (nivolumab) in relapsed multiple myeloma treated the first…
A Phase 1b trial testing a combination of Reolysin (pelareorep), Velcade (bortezomib) and dexamethasone in multiple myeloma patients who failed to respond to previous therapy…
The Phase 1b clinical trial called MUK eleven (NCT03015922) testing Reolysin (pelareorep) as a combination therapy for relapsing myeloma patients has dosed its first…
The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma…
